Monopar Therapeutics develops pharmaceutical drug candidates for Wilson disease and radiopharmaceutical cancer treatment. It last closed at $69.00 on Nov 20, down 1.84% on the day. The next earnings report for MNPR is expected around Fri, Mar 26, 2027, after the close. For the quarter ended Sep 2026, MNPR reported EPS of -$0.72 on revenue of $0. Over its last 8 reports the stock moved an average of 4.9% the session after earnings. Over the last 12 months MNPR insiders bought $105K of stock on the open market and sold $4.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is MNPR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MNPR.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on MNPRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
MNPR · as of the Nov 20 close · updated each morning
Downtrend
The stock is 3% below its 20 day and 14% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the swing low (Oct 16) at $68.81, and the nearest resistance the Pivot R1 at $70.12.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.6%/day
Key levels
$124.8252 week high+80.9%
$94.74100 day average+37.3%
$78.3650 day average+13.6%
$77.49200 day average+12.3%
$75.08Swing high (Oct 21)+8.8%
$71.0320 day average+2.9%
$70.12Pivot R1+1.6%
$69.00Last close
$68.81Swing low (Oct 16)−0.3%
$68.74Pivot−0.4%
$67.62Pivot S1−2.0%
$50.0752 week low−27.4%
Indicators
RSI (14)
39.88
Weak, oversold below 30
Neutral
MACD
-2.15
Above its signal line
Bullish
Stochastic
26.7
Middle of its range
Neutral
ADX (14)
20.2
Weak trend
Williams %R
-83.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-122.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−3.4%
Change over 10 sessions
Bearish
ATR (14)
$4.58
Typical daily range, 6.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityLow, 16.5%/day
Key levels
$124.8252 week high+80.9%
$94.74100 day average+37.3%
$78.3650 day average+13.6%
$77.49200 day average+12.3%
$75.08Swing high (Oct 21)+8.8%
$71.0320 day average+2.9%
$70.12Pivot R1+1.6%
$69.00Last close
$68.81Swing low (Oct 16)−0.3%
$68.74Pivot−0.4%
$67.62Pivot S1−2.0%
$50.0752 week low−27.4%
Indicators
RSI (14)
39.80
Weak, oversold below 30
Neutral
MACD
-2.80
Below its signal line
Bearish
Stochastic
9.8
Near the bottom of its range
Oversold
ADX (14)
24.4
Weak trend
Williams %R
-93.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-94.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−37.4%
Change over 10 sessions
Bearish
ATR (14)
$11.41
Typical daily range, 16.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for MNPR
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MNPR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow MNPR usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for MNPRHow many large options trades hit MNPR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in MNPR in the last 90 days.
From SEC Form 4 filings by MNPR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNPR is in one of them and how their past MNPR trades turned out.
Monopar Therapeutics is a pharmaceutical company based in Wilmette, Illinois, that develops drug candidates. Its candidates include ALXN1840, licensed from AstraZeneca and in development for Wilson disease, and MNPR-101, which is being developed for radiopharmaceutical use in cancer treatment. The company relies on patents and licensed intellectual property to protect these candidates.